Emerging Therapeutics in ADH1: Progress in Precision Medicine

ReachMD CME

CME credits: 1.00
Valid until: 22-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutics-in-adh1-progress-in-precision-medicine/24177/
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.